These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3753026)

  • 1. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase II study of mitoxantrone in malignant lymphoma].
    Ibuka T; Sasaki T; Imai K; Sakai Y
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2612-7. PubMed ID: 3740861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II study of mitoxantrone in advanced breast cancer].
    Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
    Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
    Kimura I; Ohnoshi T; Hiraki S; Ueoka H; Toyata K; Miyamoto H; Yamane T; Ueno K; Murashima M
    Gan No Rinsho; 1985 May; 31(6 Suppl):767-73. PubMed ID: 4040985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma].
    Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3034-9. PubMed ID: 3532959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas.
    Bajetta E; Buzzoni R; Valagussa P; Bonadonna G
    Am J Clin Oncol; 1988 Apr; 11(2):100-3. PubMed ID: 3282421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and clinical pharmacologic studies of mitoxantrone.
    Stewart JA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II study of mitoxantrone in patients with acute leukemia].
    Kimura K; Yoshikawa S; Yoshikawa H; Yamada K; Hirano M; Ikeda Y; Ohta K; Ohara K; Kobayashi M; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2573-80. PubMed ID: 3740858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II study of mitoxantrone for acute leukemia].
    Oguma S; Tatsumi Y; Hirayama F; Tani Y; Kubota Y; Kanakura Y; Ueda T; Nakamura H; Shibata H; Masaoka T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):497-501. PubMed ID: 6703723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
    Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1538-9. PubMed ID: 6347083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.